the reason I posted this as I'm actually a specialist in the psychiatry/neurology area and as NNZ-2591 is state dependant I can see it possibly having efficacy in multiple neuropsychiatric conditions, where IGF-1 has been implicated in multiple studies. Schizophrenia and possibly depression are just the tip of the iceberg! Even as an adjunct treatment in these conditions the utilisation would be huge. It would be a paradigm shift in treatment, and I would love to be involved in studies!!!
Psychiatric Indications, page-3
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.64 |
Change
-1.070(6.40%) |
Mkt cap ! $2.000B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $4.806M | 302.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 2715 | $15.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.66 | 441 | 9 |
View Market Depth
| Last trade - 14.25pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |